Ron Cohen Sells 3,620 Shares of Acorda Therapeutics Inc (ACOR) Stock
Acorda Therapeutics Inc (NASDAQ:ACOR) CEO Ron Cohen sold 3,620 shares of the business’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $20.60, for a total transaction of $74,572.00. Following the completion of the sale, the chief executive officer now directly owns 487,554 shares in the company, valued at $10,043,612.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Shares of ACOR opened at $18.63 on Friday. Acorda Therapeutics Inc has a fifty-two week low of $15.60 and a fifty-two week high of $36.35. The company has a market cap of $894.57 million, a P/E ratio of 11.33 and a beta of 1.45. The company has a current ratio of 4.03, a quick ratio of 3.95 and a debt-to-equity ratio of 0.57.
Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Wednesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.15. Acorda Therapeutics had a negative net margin of 24.88% and a positive return on equity of 13.72%. The firm had revenue of $142.80 million for the quarter, compared to the consensus estimate of $82.74 million. During the same period in the prior year, the firm earned $0.43 EPS. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. On average, research analysts forecast that Acorda Therapeutics Inc will post 0.08 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on ACOR shares. Cantor Fitzgerald started coverage on shares of Acorda Therapeutics in a research note on Thursday, August 23rd. They set a “neutral” rating and a $32.00 target price on the stock. Oppenheimer set a $18.00 target price on shares of Acorda Therapeutics and gave the stock a “hold” rating in a research note on Sunday, September 23rd. Stifel Nicolaus cut their target price on shares of Acorda Therapeutics from $25.00 to $19.00 and set a “hold” rating on the stock in a research note on Friday, October 5th. HC Wainwright set a $28.00 target price on shares of Acorda Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 24th. Finally, ValuEngine raised shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 26th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $26.56.
TRADEMARK VIOLATION NOTICE: “Ron Cohen Sells 3,620 Shares of Acorda Therapeutics Inc (ACOR) Stock” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/12/08/ron-cohen-sells-3620-shares-of-acorda-therapeutics-inc-acor-stock.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.
See Also: Cost of Capital
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.